Phase III RTOG 1010: Addition of Trastuzumab to Trimodality Treatment in Resectable HER2-Positive Esophageal Adenocarcinoma

May 29-31, 2020; Online at meetings.asco.org/am
The addition of neoadjuvant/adjuvant trastuzumab to neoadjuvant chemoradiotherapy and surgery did not improve DFS, OS, or pCR vs trimodality therapy alone in patients with HER2-positive esophageal adenocarcinoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 235 KB
Released: June 2, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

Module from Clinical Care Options (CCO): Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, discuss current treatment of cholangiocarcinoma, including the use of biomarkers

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Review this slideset on the current treatment of cholangiocarcinoma with expert perspectives from Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP.

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Released: May 13, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Video from Clinical Care Options (CCO): Expert insights on biomarker-driven treatment for gastrointestinal (GI) cancers

Pashtoon M. Kasi, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings